Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Stage IV non-squamous non-small cell lung cancer (a specific type of advanced lung cancer), confirmed by a laboratory test on a tissue or cell sample
• People whose cancer has continued to grow or spread after receiving two specific types of prior treatment: an immunotherapy drug (one that targets PD-1 or PD-L1 pathways) and a platinum-based chemotherapy
• People whose tumour has been tested and confirmed to be negative for certain gene changes (EGFR, ALK, ROS1, or others) that would point toward a different targeted treatment
• People whose cancer has at least one measurable tumour, as assessed using standard imaging guidelines (called RECIST 1.1)
• People with a life expectancy of at least 3 months
• People who are considered reasonably well and active, with a physical functioning score of 0 or 1 on a standard medical scale (called ECOG), measured within 7 days before being assigned to a treatment group
• People who are at least 18 years of age at the time of signing the consent form, of any sex or gender
• People whose organs (such as the liver, kidneys, and bone marrow) are functioning at an adequate level
• People who are able to produce sperm and who agree to either avoid penile-vaginal intercourse or use a condom, and to refrain from donating sperm, throughout the trial
• People who could become pregnant must not be pregnant (confirmed by a highly sensitive test), must not be breastfeeding, and must agree to use a highly effective form of contraception
• People who can provide an archived tumour tissue sample from a tumour that has not previously been treated with radiation
• People who can provide a fresh tumour tissue sample (taken by a new biopsy and preserved in a specific way) before being assigned to a treatment group
• People living with HIV, provided their HIV is well controlled on antiretroviral medication
• People who test positive for hepatitis B surface antigen, provided they have been on hepatitis B antiviral treatment for at least 4 weeks and their hepatitis B virus levels are undetectable before joining the trial
• People with a history of hepatitis C infection, provided the hepatitis C virus is undetectable at the screening stage

Who may not be able to join:

• People diagnosed with small cell lung cancer, or with mixed tumours that contain small cell elements
• People who have previously received radiation therapy to the lung
• People with uncontrolled or significant heart or blood vessel problems before joining the trial
• People with serious breathing difficulties caused by other lung conditions
• People who are still experiencing significant side effects (other than hair loss) from previous cancer treatments that have not recovered to a mild level or returned to their normal baseline
• People with a known severe allergic reaction (Grade 3 or higher) to the study drug or any of its ingredients
• People with a clinically significant disease affecting the cornea of the eye
• People who have had radiotherapy within 2 weeks before starting the study drug, or who still have radiation-related side effects requiring steroid medication
• People who have not waited long enough after previous treatments before joining the trial (confirm with trial site)
• People who have received a live or live-attenuated vaccine within 30 days before the first dose of the study drug
• People with a diagnosis of an immune system deficiency, or who are regularly taking steroid medication that affects the whole body
• People who have previously been treated with a chemotherapy drug called docetaxel, either alone or in combination with other treatments
• People who have taken part in another clinical trial using an experimental drug or device within 4 weeks before starting this study
• People with another cancer that is either still growing or has required active treatment within the past 3 years
• People with known untreated cancer that has spread to the brain or spinal fluid lining
• People with evidence of cancer spreading to the membranes surrounding the brain or spinal cord (leptomeningeal disease)
• People with a history of, or current or suspected, inflammatory lung disease (called interstitial lung disease or pneumonitis)
• People with an active autoimmune disease that has required treatment affecting the whole body within the past 2 years
• People with an active infection that requires treatment affecting the whole body
• People living with HIV who also have a history of Kaposi's sarcoma or a condition called Multicentric Castleman's Disease
• People with active inflammatory bowel disease requiring immune-suppressing medication, or a clear prior history of inflammatory bowel disease
• People with a known history of, or currently active, a neurological condition linked to cancer called a paraneoplastic syndrome
• People who have had an organ or tissue transplant from another person
• People who have not fully recovered from major surgery, or who still have ongoing complications from surgery

Important: Always verify eligibility with the trial site directly before applying.